Carl Icahn is no stranger to boardroom battles. On Monday, the longtime equity-shakeup artist fired off his third letter in as many weeks to Biogen Idec
Whether with Yahoo!
Icahn claimed that Biogen's current board of directors was asleep at the wheel while multiple drugmakers were considering placing a bid on Biogen last year. Because of Biogen's "missteps" and "poor design" of the bidding process, Icahn charged that all the potential bidders are now locked out "from talking to (Biogen) about an acquisition".
The way the bidding process shook out last year has always been Icahn's biggest complaint about Biogen's recent performance. He balked when rumors briefly swirled earlier in the year that Biogen might be looking to make a large acquisition of its own, but overall, he has made few complaints about Biogen's operational performance. With revenue up 18% and free cash flow up 15% last year, despite a tough operating environment for many drugmakers, Icahn would have trouble arguing that Biogen is failing operationally.
Perhaps tellingly, yesterday several independent shareholder-advisory firms sided against voting for Icahn's slate of board nominees. Even if Icahn succeeds at the company's annual meeting, adding a few more independent directors to Biogen's board won't give him control over Biogen by any means.
More from The Motley Fool
Will 2018 Be Biogen Inc.'s Best Year Yet?
You probably don't want to bet the farm on it.
5 Biotech Buyout Candidates for 2018
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
Biogen Inc. Buys Its Way Out of Competition
The big biotech gains rights to a potential Tecfidera competitor from Alkermes.